The role of 39 psoriasis risk variants on age of psoriasis onset. by Lu, Yingchang et al.
UCSF
UC San Francisco Previously Published Works
Title
The role of 39 psoriasis risk variants on age of psoriasis onset.
Permalink
https://escholarship.org/uc/item/3jj5577r
Authors
Lu, Yingchang
Kane, Sinae
Chen, Haoyan
et al.
Publication Date
2013
DOI
10.1155/2013/203941
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Hindawi Publishing Corporation
ISRN Dermatology
Volume 2013, Article ID 203941, 4 pages
http://dx.doi.org/10.1155/2013/203941
Research Article
The Role of 39 Psoriasis Risk Variants on Age of Psoriasis Onset
Yingchang Lu,1 Sinae Kane,1 Haoyan Chen,1,2 Argentina Leon,1 Ethan Levin,1
Tien Nguyen,1 Maya Debbaneh,1,3 Jillian W. Millsop,1,4 Rishu Gupta,1,5 Monica Huynh,1,6
Daniel Butler,1 Kelly Cordoro,1 and Wilson Liao1
1 Department of Dermatology, University of California San Francisco, 2340 Sutter Street, P.O. Box 0808,
San Francisco, CA 94143-0808, USA
2Department of Gastroenterology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine,
Shanghai Institute of Digestive Diseases, Shanghai 200001, China
3University of California Irvine School of Medicine, Irvine, CA 92697, USA
4University of Utah School of Medicine, Salt Lake City, UT 84132, USA
5 Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
6Chicago College of Osteopathic Medicine, Downers Grove, IL 60515, USA
Correspondence should be addressed to Wilson Liao; liaowi@derm.ucsf.edu
Received 16 July 2013; Accepted 29 August 2013
Academic Editors: B. Amichai, G. Chodorowska, C. Ferra´ndiz, and A. Tosca
Copyright © 2013 Yingchang Lu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Recent genome-wide association studies (GWAS) have identified multiple genetic risk factors for psoriasis, but data on their
association with age of onset have been marginally explored. The goal of this study was to evaluate known risk alleles of psoriasis
for association with age of psoriasis onset in three well-defined case-only cohorts totaling 1,498 psoriasis patients. We selected 39
genetic variants from psoriasis GWAS and tested these variants for association with age of psoriasis onset in a meta-analysis. We
found that rs10484554 and rs12191877 nearHLA-C and rs17716942 near IFIH1 were associated with age of psoriasis onset with false
discovery rate < 0.05. The association between rs17716942 and age of onset was not replicated in a fourth independent cohort of
489 patients (𝑃 = 0.94). The imputed HLA-C∗06:02 allele demonstrated a much stronger association with age of psoriasis onset
than rs10484554 and rs12191877. We conclude that despite the discovery of numerous psoriasis risk alleles, HLA-C∗06:02 still plays
the most important role in determining the age of onset of psoriasis. Larger studies are needed to evaluate the contribution of other
risk alleles, including IFIH1, to age of psoriasis onset.
1. Introduction
Psoriasis is an inflammatory, immune-mediated disorder of
the skin, joints, and nails with an estimated prevalence of
2-3% of the population. Henseler and Christophers divided
psoriasis into two subtypes. Type I psoriasis manifests before
age 40 with peak onset at 16–22 years, and Type II psoriasis
begins after age 40 with peak onset at 57–60 years [1]. Type
I and II psoriasis have been shown to differ clinically in
their severity, relapse frequency, and family history [1, 2].
The clinical differences in Type I and Type II psoriasis
are paralleled by genetic differences. Type I psoriasis has a
stronger genetic basis as a greater proportion of patients had
a family history of psoriasis, and has stronger HLA-C∗06
associations; however, Type II psoriasis is negative in family
history, and is not associated with HLA-C∗06 [1, 3, 4]. Over
the past few years, over 36 novel psoriasis loci have been
identified through genome-wide association studies (GWAS)
[5–13]. However, it is not known to what degree these
susceptibility alleles influence the age of onset of psoriasis.
Here, we examined 39 of these genetic variants in 3 cohorts
of psoriasis cases to ascertain whether any of these loci were
preferentially associated with the age of psoriasis onset.
2. Materials and Methods
The SNPs were selected from psoriasis GWAS conducted in
Caucasian populations (published before December 2012;
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see Supplementary Table 1 available online at http://dx.doi
.org/10.1155/2013/203941), taking into account the potential
molecular mechanisms underlying the pathogenesis of pso-
riasis [14]. We evaluated 39 SNPs for association with age of
psoriasis onset in two psoriasis GWAS case cohorts; 13 of
those SNPs were genotyped by Illumina GoldenGate assay
in a third cohort of 418 cases at the University of California
San Francisco (UCSF) (Table 1). rs17716942 in IFIH1 was
genotyped in a fourth independent cohort of 489 National
Psoriasis Foundation (NPF) cases using the Applied Biosys-
tems Taqman genotyping assay. Age of onset of psoriasis was
determined by patient self-report and by the treating der-
matologist. The two GWAS cohorts consisted of the Genetic
Association Information Network (GAIN) cohort including
898 cases [7] and the Washington University/University of
California San Francisco cohort (WashU/UCSF) including
182 cases [6]. IMPUTE2 [15] was used to impute the ungeno-
typed SNPs in these two case cohorts by using phase 3
HapMap and 1000 Genomes pilot project CEU haplotypes
as a reference. Since the distributions of the age onset of
psoriasis in our four independent case cohorts were not
bimodal but positively skewed (Supplementary Figures 1–4),
a square-root transformed age onset was used in the analysis.
The linear regression quantitative trait test in SNPTEST was
used to associate the imputed dosage for each SNP with the
age onset of psoriasis separately in GAIN and WashU/UCSF
cohorts with the adjustment of gender. Only imputed SNPs
with relatively high confidence (PROPER Info > 0.5) were
analyzed [16]. The association results from the GAIN cohort,
WashU/UCSF cohort, and UCSF cohort were then combined
by meta-analysis using inverse-variance method based on a
fixed-effect model. The false discovery rate method was used
to correct for multiple testing (FDR 𝑞 < 0.05).
3. Results
We used linear regression to evaluate the association of 39
psoriasis genetic loci with age of psoriasis onset in a com-
bined sample of 1,498 cases. These loci were identified by
previous psoriasis genome-wide association studies and
include variants within or near the HLA locus, IL23R,
IL12B, TNIP1, TNFAIP3, IL23A, IL13, TRAF3IP2, LCE3B/3C,
RNF114, IFIH1, ERAP1, REL, TYK2, NFKBIA, NOS2, IL28RA,
SDC4, FBXL19, and RPS26. We found that rs10484554 and
rs12191877 nearHLA-C and rs17716942 near IFIH1were asso-
ciated with age onset of psoriasis with FDR q value < 0.05. As
expected, the alleles associatedwith increased risk of psoriasis
were also associated with younger age of onset of psoriasis
(Table 1). However, the association between rs17716942 and
age of psoriasis onset was not replicated in the NPF cases
(beta = −0.01 and 𝑃 = 0.94 for the T allele, Table 1).
Since the top two SNPs associated with age of onset were
located near the HLA-C locus, we further imputed HLA-
C∗06:02 in GAIN, WashU/UCSF, and UCSF case cohorts as
previously described [17]. HLA-C∗06:02 was more strongly
associated with age of onset than the two individual HLA-
C SNPs (Table 1). Our linear regression model revealed that
psoriasis patients with two copies of HLA-C∗06:02 devel-
oped psoriasis on average at age 15, psoriasis patients with
one copy of HLA-C∗06:02 developed psoriasis at age 21,
and psoriasis patients with zero copies of HLA-C∗06:02
developed psoriasis at age 27. Thus, each additional copy of
HLA-C∗06:02 reduced the onset of psoriasis by 6 years.
4. Discussion
In this study we found that among the many psoriasis loci
discovered by GWAS, only the HLA-C locus showed robust
evidence of playing a role in earlier psoriasis onset.TheHLA-
C∗06:02 allele had a stronger effect on age of onset than
individualHLA-C SNPs, and this allele was highly significant
in each of the three individual cohorts studied (𝑃 < 0.001).
In our study population, psoriasis patients with two copies of
HLA-C∗06:02 developed psoriasis nearly 12 years earlier than
those without HLA-C∗06:02. This is likely to underestimate
the true effect ofHLA-C∗06:02 because our study population
contained relatively more type I psoriasis (onset < age 40)
than type II psoriasis (onset > age 40) (Supplementary
Figures 1–4), where it has been shown that C∗06:02 is more
common in type I psoriasis compared to type II psoriasis
[1, 3, 4].The SNP rs17716942 in the innate antiviral gene IFIH1
was also significant in the meta-analysis (𝑃 = 0.002, FDR <
0.05). IFIH1 encodes a cytoplasmic helicase that acts as a
sensor for double-stranded RNA. However, this SNP was not
significantly associated with age of onset when examined in
an independent cohort, thus further examination of this gene
in additional cohorts is warranted.
Genetic variations in ERAP1, IL23R, and LCE3B/LCE3C
have recently been associated with pediatric-onset psoriasis
(onset < age 18) in a small study [18]. However, in that study
the same variants were also shown to be associated with
adult-onset psoriasis, suggesting, they may not be specific
to pediatric-onset psoriasis. In our study, LCE3B/LCE3C was
significantly associated with age of onset in the GAIN cohort
(𝑃 = 0.007), but not in themeta-analysis (FDR=0.17).Wedid
not observe any evidence for association of ERAP1 or IL23R
in our data.
Considering that HLA-C∗06:02 has a much larger effect
size (odds ratio> 3.0) on the risk of developing psoriasis com-
pared to the other psoriasis risk alleles (odds ratios < 2.0), it
is possible that some of these other risk alleles have a smaller
influence on age of onset that would only be detected in a
study of larger sample size. There could also be a cumulative
additive effect of psoriasis risk alleles on age of onset. Indeed,
it has previously been shown that a genetic risk score that
combines the genetic burden of the top ten psoriasis genes is
significantly higher in patients who develop psoriasis before
age 30 compared to those who develop psoriasis after age 30
[19].
In summary, in a large dataset of 1,498 cases we have
examined 39 psoriasis variants for their association with age
of psoriasis onset. Only the HLA-C locus demonstrated
robust evidence of association with age of onset, with HLA-
C∗06:02 having the strongest effect. In the meta-analysis a
variant in IFIH1was also found to be significant, however this
SNP was not replicated in an independent cohort. Further
studies are needed to clarify the role of genetic variants on
the age at which psoriasis manifests.
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